BioWorld Science has now been migrated onto the same platform as the full suite of BioWorld news services, providing an improved experience and expanded news offering.
The new site features many enhancements, which you can read about here. Frequently Asked Questions are answered here.
In addition to BioWorld Science content, you can now read headlines and summaries from the flagship news service, BioWorld, as well as BioWorld MedTech and BioWorld Asia. You’ll also find access to special reports and the BioWorld Insider podcast.
We're excited to offer an upgraded experience and thank you for reading. Read More
“The association between air pollution and lung cancer is not new,” Charles Swanton told the audience at the European Society of Medical Oncology (ESMO) 2022 Congress. But as with so many associations, causation has been hard to establish, partly due to the puzzling absence of mutations. Read More
Merck KGaA provided details on the discovery of MSC-4106, an orally active lead compound binding to the lipidation pocket (P-site) of the TEAD1 transcription factor and capable of disrupting its interaction with the transcriptional cofactors YAP and TEAZ, thereby preventing the formation of the YAP/TAZ-TEAD transcriptional complex. Read More
The PKMYT1 kinase has emerged as a promising therapeutic target for CCNE1-amplified cancers, after a recently reported genome-scale CRISPR/Cas9-based screen identified its inhibition as synthetically lethal for CCNE1 amplification. Read More
Intravacc BV has announced additional preclinical and toxicology data for Avacc 10, the company's SARS-CoV-2 intranasal candidate vaccine, showing a reduction in upper respiratory tract viral load, broad cross protection against circulating variants of concern and a promising safety profile. Read More
China's National Medical Products Administration (NMPA) has cleared CSPC Pharmaceutical Group Limited to conduct clinical trials of TG-103 injection for the treatment of Alzheimer's disease and for the treatment of nonalcoholic steatohepatitis (NASH). Read More
Researchers from CNRS and the Université d'Orléans presented the discovery of novel inhibitors of LIM kinases (LIMKs) as potential therapeutic candidates for the treatment of osteosarcoma (OS). Read More
Galecto Biotech AB has discovered β-D-galactopyranose compounds acting as galectin-1 (LGALS1) and/or galectin-3 (LGALS3) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, fibrosis and cardiovascular, eye, metabolic, cerebrovascular and inflammatory disorders, among other disorders.
Proof of concept has been achieved for a therapy for argininosuccinic aciduria consisting of human argininosuccinic lyase (ASL) mRNA encapsulated in lipid nanoparticles (ASL-LNPs). Read More
Forge Therapeutics Inc. has synthesized new UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) (bacterial) inhibitors reported to be useful for the treatment of Gram-negative bacterial infections. Read More
Gilead Sciences Inc. has described thienopyrrole compounds acting as Toll-like receptor 7 (TLR7) and/or TLR8 antagonists reported to be useful for the treatment of systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis and inflammatory disorders, among other disorders. Read More
More than 70% of individuals with diabetes develop some form of heart disease. Nonischemic diabetic heart disease (NiDHD) is a chronic complication characterized by ventricular dilation and hypertrophy, diastolic dysfunction, and decreased or preserved systolic function, and eventually may result in heart failure. Read More
Qilu Regor Therapeutics Inc. has identified (hetero)arylamino-cyclohexyl-sulfonyl derivatives acting as C-C chemokine receptor type 6 (CCR6) antagonists reported to be useful for the treatment of inflammatory bowel disease, Crohn's disease and ulcerative colitis. Read More
